Filing Flows

Filing Flows › Companies › Sonoma Pharmaceuticals › Cash flow

Sonoma Pharmaceuticals cash flow, quarter by quarter

Latest: Q1 FY27 · from the cash-flow statements filed with the SEC

Free cash flow−$651K in Q1 FY27 · −$2.7M over twelve months

Operating cash flow−$649K
Capital spending−$2K
Free cash flow−$651K
Cash conversion cycle80 days

Analysis

In Q1 FY27, Sonoma Pharmaceuticals generated −$649K of operating cash flow and spent $2K on capital projects, leaving free cash flow of −$651K. That is $1.5M more than in Q1 FY26 (−$2.1M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$2.6M; the largest uses were operating cash flow ($2.6M), net borrowing (+) / repaid (−) ($272K), capital spending ($88K); besides operations, cash came from shares issued ($4.0M), other financing ($277K); the cash balance rose by $1.7M.

Operating cash flow was −$649K against net income of −$330K. The largest differences: receivables −$650K, inventory −$81K, stock-based pay +$58K.

Its cash conversion cycle was 80 days (receivables 41 + inventory 88 − payables 49).

Free cash flow

Sonoma Pharmaceuticals: free cash flow by quarterSonoma Pharmaceuticals: free cash flow by quarter$328KQ2 FY25$563KQ3 FY25−$142KQ4 FY25−$2.1MQ1 FY26−$645KQ2 FY26−$811KQ3 FY26−$548KQ4 FY26−$651KQ1 FY27
Operating cash flow less capital spending.
Sonoma Pharmaceuticals: operating cash flow against capital spendingSonoma Pharmaceuticals: operating cash flow against capital spendingOperating cash flowCapital spending$354K$26KQ2 FY25$565K$2KQ3 FY25−$95K$47KQ4 FY25−$2.0M$106KQ1 FY26−$635K$10KQ2 FY26−$764K$47KQ3 FY26−$519K$29KQ4 FY26−$649K$2KQ1 FY27
Latest (Q1 FY27): Operating cash flow −$649K, Capital spending $2K.

Capital allocation, year by year

Sonoma Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearSonoma Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY22: Operating cash flow −$4.2MFY22: Net borrowing $63KFY22: Shares issued $7.8MFY22: Capital spending −$137K$7.8MFY22FY23: Operating cash flow −$6.2MFY23: Net borrowing −$1.0MFY23: Shares issued $2.9MFY23: Capital spending −$269K$2.9MFY23FY24: Operating cash flow −$2.4MFY24: Net borrowing −$481KFY24: Shares issued $1.8MFY24: Capital spending −$2K$1.8MFY24FY25: Operating cash flow −$88KFY25: Net borrowing −$404KFY25: Shares issued $3.2MFY25: Capital spending −$80K$3.2MFY25FY26: Operating cash flow −$3.9MFY26: Net borrowing −$271KFY26: Shares issued $471KFY26: Capital spending −$192K$471KFY26
Over these 5 years operating cash flow totalled −$16.8M; the largest uses were operating cash flow ($16.8M) and net borrowing ($2.2M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$5.3M
Debt$140K
Net cash$5.2M
Cash runway2.0 years

Sonoma Pharmaceuticals is burning cash: its operations consume cash, a free cash flow of −$2.7M a year at the current rate against $5.3M of cash and investments: a runway of about 2.0 years before any new financing.

Where the cash came from and went

Sonoma Pharmaceuticals: sources (+) and uses (−) of cash, Q1 FY27Sonoma Pharmaceuticals: sources (+) and uses (−) of cash, Q1 FY27Shares issued$3.5MCash drawn (+) / kept (−)−$2.9MOperating cash flow−$649KExchange rates$136KNet borrowing (+) / repaid (−)−$82KCapital spending−$2K
Sonoma Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q1 FY27Sonoma Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q1 FY27Shares issued$4.0MOperating cash flow−$2.6MCash drawn (+) / kept (−)−$1.7MExchange rates$399KOther financing$277KNet borrowing (+) / repaid (−)−$272KCapital spending−$88K

From profit to cash

Sonoma Pharmaceuticals: net income to operating cash flow, Q1 FY27Sonoma Pharmaceuticals: net income to operating cash flow, Q1 FY27Net income−$330KDepreciation & amortization$32KStock-based pay$58KReceivables−$650KInventory−$81KDeferred revenue−$8KPrepaid and other assets$40KOperating cash flow−$649K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q1 FY2741884980
Q4 FY2640984890
Q3 FY265412552127
Q2 FY2644984696
Q1 FY265512053121
Q4 FY255612247131
Q3 FY257212043148
Q2 FY258211432165

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q1 FY27−$649K−$2K−$82K$3.5M−$2.9M−$651K
Q4 FY26−$519K−$29K−$51K$161K$162K−$548K
Q3 FY26−$764K−$47K−$56K$266K$474K−$811K
Q2 FY26−$635K−$10K−$83K$21K$570K−$645K
Q1 FY26−$2.0M−$106K−$81K$23K$1.8M−$2.1M
Q4 FY25−$95K−$47K−$81K$49K−$138K−$142K
Q3 FY25$565K−$2K−$82K$790K−$1.2M$563K
Q2 FY25$354K−$26K−$122K$1.6M−$1.5M$328K

Sonoma Pharmaceuticals: income statement and cash flow

Sonoma Pharmaceuticals, Q1 FY27: revenue $6.4M (+60% year over year), operating margin -0.6%. The chart follows the revenue to costs, profit and cash.

Sonoma Pharmaceuticals: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.